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ABSTRACT 
 
Spectroscopic Investigation of the Effect of Polyphenolic Compounds on the Amyloid-β 
Protein 
Brittany Hagenhoff 
 
Aggregation of the amyloid-β (Aβ) protein is associated with the development of 
Alzheimer’s disease.  Aβ is a 39-43 residue cleavage product of the amyloid precursor 
protein (APP).  Aβ aggregates to produce insoluble plaques in the brain, which are 
composed of cross β-sheet structured fibrils. Various polyphenolic compounds, both 
naturally occurring and synthetic, have been shown to interfere with Aβ aggregation.  
To evaluate the ability of specific polyphenols to prevent Aβ aggregation, this 
investigation utilized nordihydroguaiaretic acid, curcumin, rosmarinic acid, resveratrol, 
piceatannol, and diethylstilbestrol.  These polyphenols differ in the number of ring 
substituents and the atom linker between the rings. The interaction of Aβ with the 
polyphenolic compounds was analyzed using circular dichroism (CD) and deep 
ultraviolet resonance Raman (dUVRR) spectroscopies.   
The polyphenols diethylstilbestrol, resveratrol, and piceatannol have increasing 
numbers of hydroxyl substituents on their rings, having two, three, and four 
respectively.  It was found that with increasing number of hydroxyl ring substituents, the 
protein remained predominantly disordered and prevented formation of β-structure in 
the protein and aided in the destabilization of pre-formed Aβ fibrils. Decreasing the 
number of hydroxyl substituents increases the likelihood of β-sheet formation, 
 xii 
prevented destabilization of pre-formed Aβ fibrils, and induced loss of stability of the 
protein.  
The polyphenols nordihydroguaiaretic acid, curcumin, and rosmarinic acid have 
increasing polarity respectively in the chain linker between the phenolic rings. Each of 
these polyphenols have four ring substituents and have four to six atoms in their chain 
linker. It was found that with increasing the polarity of the linker, the protein had a 
greater tendency to form a β-structure, however pre-formed Aβ fibrils were destabilized 
efficiently by all three polyphenols. Though a nonpolar chain linker pushed fibrillar 
protein toward a more disordered structure initially, the final state was similar 
regardless of added polyphenol.  
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Chapter I: Introduction 
1.1   Alzheimer’s Disease 
Alzheimer’s disease (AD) is a leading cause of dementia in people above the age 
of 65 and the sixth leading cause of death in the United States (Figure 1.1).  AD is an 
irreversible neurodegenerative disease, and is characterized by synaptic failure, 
neuronal damage, and cellular degeneration in regions of the brain that mediate 
memory and cognitive function.[1,2,3]  Diagnosis of AD is difficult as there is no single test 
that can diagnose the disease. AD accounts for about 60-80% of all diagnosed dementias 
with diagnosis made based upon clinical history, documentation of functional decline, 
and the ruling out of all other forms of dementia. A conformation of the diagnosis 
cannot be made until autopsy.[1,4] 
There are two main hallmarks associated with AD which are senile plaques and 
neurofibrillary tangles in the plasma and cerebrospinal fluid in the brain.  Plaques, which 
are made up of the Aβ protein, are believed to interfere with neuron communication at 
synapses.[1,2] Neurofibrillary tangles are made up of the tau protein and interfere with 
nutrient transport in neurons. [1-2,5-6]   
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Figure 1.1:  Diagnosis of Alzheimer’s disease is on the rise, projected to reach nearly 14 million by 
year 2050.  One in nine people over 65 years of age have the disease, with two out of every three 
of those being women.[1] 
 
1.2   Diet and AD Prevalence   
In 2010, there was an estimated 35.6 million people worldwide suffering with 
dementia with projections of over 65 million by 2030.[7]  There are many different forms 
of dementia including vascular dementia, Lewy body dementia, frontotemporal 
dementia, normal pressure hydrocephalus dementia, and mixed dementia, all with 
common outward symptoms such as cognitive impairment and memory loss with about 
60-80% of these diagnoses being AD.[4] The prevalence of dementia in 2010 was 2.6% in 
Africa, 3.9% in Asia, 6.2% in Europe, and 6.5% in the Americas. [7]   Many ethnic groups 
living in the United States have much higher AD prevalence rates than those living in 
their homelands.[7] Studies of these populations show that 6.24 % of Nigerians living in 
the United States suffered from AD whereas only 1.41% of Nigerians suffered in Ibadan, 
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Nigeria. In the United States, 4.1% Japanese suffered from AD, while AD prevalence in 
Japan was only 1.88%.[8-10]  
The prevalence of AD among different ethnicities in the United States is roughly 
ranked as African Americans and Hispanics > American and European whites > Asian 
Americans > Native Americans.[1,7,11]  One of the primary differences among these ethnic 
groups is that they vary in location.  A potentially unifying factor that could influence the 
chance of developing AD may be location and more specifically, diet. Different 
ethnicities and cultures have different eating and drinking habits, which could very well 
be one of the factors at the root of the differences in AD prevalence.  
As one would assume, eating healthy should keep your overall health in good 
standing. The food pyramid is one representation of a healthy diet. However, which 
foods comprise the food pyramid varies depending on region.  In general, high 
consumption of meat, butter, high-fat dairy products, eggs, refined sugar, saturated 
fatty acids, high caloric intake, and excessive alcohol consumption has a negative 
association with brain health, whereas diets rich in fruits, vegetables, fish, tea, coffee, 
and whole grains has a positive association.[12-13]  A diet that follows this general trend of 
high fresh food intake and low meat and fat intake is the Mediterranean diet.  The 
Mediterranean diet consists of:[13-17]   
▪ High intake of vegetables, legumes, fruits, nuts and seeds, potatoes, breads and 
cereals, and olive oil 
▪ Moderate intake of fish 
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▪ Low to moderate intake of dairy products (cheese and yogurt) from goat, sheep, 
buffalo, cow and camel 
▪ Low intake of meat and poultry 
▪ Low to moderate amount of alcohol wine 
▪ Condiments, i.e., garlic, onion, and herbs 
▪ Desserts of fresh fruit or sweets containing concentrated sugars or honey  
Olive oil is the main source of fat, unlike in Western diets where animal fats are 
more common.  Also, Western diets are higher in dairy products. [14-16]  The traditional 
Japanese diet is similar to the Mediterranean diet in that it is made up of mainly fish and 
plant foods, and is limited in animal fats.[31]  Conversely, the Western diet is comprised 
mostly of red and processed meats, refined grains, sweets, and moderate alcohol 
intake.[15,17]  These differences could be the reason that AD prevalence is higher in the 
U.S and Northern Europe than in the Mediterranean region and Japan.  
Adherence to a healthy diet, much like the Mediterranean diet has been 
associated with reduced risk of cardiovascular disease and cancers, lowered rates of 
chronic diseases, reduced risk of neurodegenerative disease, reduced risk of AD, better 
cognitive functioning, and overall longer life expectancy.[13,18-21] 
1.3   Amyloid-β 
The buildup of the Aβ protein into plaques is a hallmark of AD.[1]    Aβ is a ~4 kDa 
protein that is 39-43 residues long. It is produced from the proteolytic cleavage of the 
transmembrane amyloid precursor protein (APP) by β-secretase and γ-secretase.[22-24] 
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Once Aβ is cleaved from APP, the monomer can self-aggregate into various sized 
oligomers.[25-27]  The oligomers are transient in nature, changing size and structure 
quickly, making individual species difficult to isolate. The suggested mechanism in which 
the aggregation occurs (Figure 1.2) can differ for each oligomeric species as well. 
Unsystematic intermediates can form between monomers and oligomers before 
forming a fibril.[25-26, 28-29]   
One type of intermediate that can form is the protofibril. Protofibrils are short, 
flexible fibrils which are precursors of longer, more rigid fibrils.[28-29]  The occurrence of 
protofibrils decreases as fibril formation increases.[29]  The process of fibril formation by 
protofibril aggregation into mature fibrils is irreversible; they do not dissociate into 
protofibrils.[29] All forms of Aβ from monomers to high molecular weight oligomers have 
proven to be neurotoxic.[23]   
 
Figure 1.2:  Proposed aggregation mechanism of Aβ. 
The different species present in the aggregation pathway can take on different 
types of protein secondary structure.  The Aβ monomer is disordered in structure and as 
the protein begins to aggregate, it becomes more ordered forming β-sheet secondary 
structure.[25-26,28-29] These secondary structures are based on the dihedral angles around 
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Cα of an amino acid in the protein backbone, phi and psi.[30] The disordered secondary 
structure means there is no order, or more specifically, no one set of dihedral angles. 
The β-sheet secondary structure can be categorized into two types; parallel and anti-
parallel. Parallel β-strands align themselves in the same direction with carbonyl and 
amide groups staggered. Anti-parallel β-strands align themselves in opposite directions 
with carbonyl and amide groups lining up. Parallel β-sheets have phi and psi angles of 
119o and 113o, respectively, and anti-parallel β-sheets have phi and psi angles of -139o 
and 1350, respectively.[31]   
1.4   Polyphenols  
1.4.1   Polyphenols and Aβ 
Polyphenols have been shown to reduce the toxicity of various forms of Aβ and 
play a role in the Aβ aggregation process.[32]  Structurally, polyphenols are aromatic 
rings with hydroxyl group substituents that are naturally found in plants and foods with 
over 8,000 compounds identified.[32-33]   
As previously mentioned, Aβ can self-aggregate in various ways and into various 
sized oligomers, changing in size and structure quickly.[25-29]  Although the exact 
mechanism is unknown, a general classification of polyphenols based on how they act 
on the aggregation of Aβ can be made. The three classifications are those that prevent 
the formation of fibrils, those that prevent the extension of fibrils, and those that can 
destabilize pre-formed fibrils.[33,35]   
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1.4.2   Structural Differences (Hydrophobicity vs Antioxidant Potency)  
Polyphenols vary widely in structure. They can be sub-classified into many 
groups based on structure, such as flavonoids, stilbenes, or lignans. The flavonoid group 
is the largest polyphenol group, with over 6,000 flavonoids identified, and has sparked 
research in many areas.[32-33,36]   All flavonoids have a similar (C6-C3-C6) structure with 
two aromatic rings bound by a 3-carbon formed oxygenated heterocycle which makes 
up a third ring, and differ mainly in the substituents on the rings.[37]  Stilbenes have a 
similar structure to flavonoids except for one less carbon that prevents the third ring 
from forming (i.e., C6-C2-C6).  Instead, the two rings are connected by a double bond; 
i.e., methylene bridge.[32,37]  Lignans are a combination of two phenylpropane units 
where two C6-C3 structures are attached at their central (C8) carbon.[32-33,38]  Some 
polyphenols do not fall into a specific classification and are grouped as an “other 
polyphenol”.  
Flavonoids have been heavily researched due to their vast abundance. However, 
the focus of this research is on non-flavonoid polyphenols such as stilbenes and other 
polyphenols. Depending on the classification of the polyphenol, different structural 
characteristics are present.  In this investigation, the polyphenols used were each linear 
polyphenols (non-flavonoid) each with two rings, a chain linker between the rings, and 
hydroxyl group substituents on the rings.  
Polyphenols can act upon any stage of the Aβ aggregation process, with certain 
structural characteristics suiting early or late stages more appropriately. Recent studies 
have surfaced that deal with the structural significance of polyphenols. [34,38-39]  Certain 
 8 
characteristics that can play a role on how it will behave are the number and type of 
substituents on the rings, length of the atom linker between the rings, and the polarity 
of the atom linker.  An example of a generic polyphenol is shown in Figure 1.3.   
 
Figure 1.3:  Generic polyphenol model: hydroxyl group substituents (blue), aromatic rings (red), 
and an atom linker chain (yellow). 
 
1.4.3   Polyphenol Structural Characteristics 
Hydrophobicity and antioxidant potency of polyphenols have been shown to 
affect their ability to inhibit Aβ aggregation. It is believed that hydrophobicity interferes 
with the formation and extension stages, whereas antioxidative potency affects the 
fibrillization stages.[34]   Two rings with a minimum of two to three hydroxyl substitutions 
on those rings is preferred.[34]   Polyphenols can interact with proteins through a 
multitude of ways, including aromatic π-π stacking interactions between the 
polyphenolic rings and aromatic residues, hydrogen bonding between the hydroxyl 
substituents and the protein backbone, and hydrophobic interactions.[34,40-45]   
Structurally, a polyphenol with both high hydrophobicity and antioxidant 
potency would be the most desirable for preventing Aβ aggregation. This would allow 
binding to hydrophobic motifs of the protein, interference with aromatic stacking that 
could facilitate aggregation, formation of hydrogen bond which could weaken salt 
bridges between aggregating Aβ species, and provide free radical scavenging.[34]  
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Binding of each individual polyphenol to the Aβ protein not only depends on the 
polyphenol’s structure but also which Aβ species it is binding to along the aggregation 
pathway. Disordered monomers versus small oligomers versus β-sheet fibrils will bind 
polyphenols by different means due to their variation of secondary and higher order 
structure. Typically, polyphenols interact with the peptide at residues such as tyrosine-
10 and phenylalanines-4, 19, and 20 due to π-stacking interactions of the aromatic 
residues with the phenolic rings of the polyphenol.[46-47]   
Isolated segments of the protein change in secondary structure differently. For 
example, the C-terminus has a higher probability of rapid oligomerization due to the 
increased number of nonpolar residues.[46]  Lührs et al. showed two parallel β-sheets 
that run along the fibril axis from residues ≈18-26 and ≈31-42 through the use of 
hydrogen/deuterium-exchange nuclear magnetic resonance (NMR) spectroscopy.[48]  
Polyphenols interacting with residues within this region could prevent the β-strands 
from developing. Polyphenols such as curcumin have been shown to interact with 
residues in this region including phenylalanines-19 and 20, serine-26, isoleucine-32, and 
methionine-35 as well as within the loop of these β-strands at lysine-28.[47-48]  Once β-
strands have formed, polyphenols such as rosmarinic acid and resveratrol, have been 
shown to hydrogen bond along the side of β-sheet amyloid structures promoting 
destabilization of fibrils.[47,49]   
1.5   Polyphenols and Oxidation 
Polyphenols are famous for their antioxidative properties and are abundant in 
fruits, vegetables, and beverages, such as tea and red wine.  Free radicals are products 
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of naturally occurring processes in cells, which in turn cause oxidative stress in the cells 
that can lead to cell death.  Antioxidants remove free radicals by scavenging them.[50]  
Polyphenols have been known to possess hepatoxic, antioxidant, anti-inflammatory, 
antimicrobial, anticancer, antiviral, anti-allergic, and anti-ulcer effects.[33]  Polyphenols 
have many different biological actions, such as interaction with transition metals, 
inactivation of free radicals, precipitation of protein, inhibition of inflammatory 
response, modulation of the activity of different enzymes, and effects on intracellular 
signaling pathways and gene expression.[51-54]   
Reactive oxygen species (ROS) are free radicals with a single unpaired electron 
that are produced during naturally occurring cellular processes that can damage 
proteins, nucleic acids, and lipid membranes leading to membrane instability eventually 
causing apoptosis. [55-56]  Oxidative stress occurs when the generation of ROS is higher 
than the level of antioxidants acting against them. Examples of ROS are superoxide 
anions (O2·-), hydroxyl radicals (OH·), and hydrogen peroxide (H2O2).[57]  Increasing 
polyphenol intake can combat ROS generation due to the ability of polyphenols to 
donate a hydrogen atom to lipids and other molecules, thereby preventing their 
oxidation by ROS.[54]   
Protein oxidation and increased oxidative stress has been shown in numerous 
studies to lead to the manifestations of AD.[57-58]  The brain is particularly susceptible to 
free radical damage due to a high content of easily peroxidizable lipids, a high rate of 
oxygen consumption, and a lack of antioxidants in relation to other organs in the 
body.[2,58-59]  Protein oxidation impairs protein synthesis, neuronal function, enzyme 
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activation, and the ability of cells to regulate homeostasis leading to cognitive 
decline.[59-60]  
ROS produce oxidative stress which induces intracellular Aβ accumulation in cell 
cultures and Aβ itself has been shown to induce oxidative stress in vivo and in vitro.[36,62-
66]   Studies have shown that lipid peroxidation is enhanced by increases in intracellular 
Aβ.[63]  The oxidation of the methionine-35 residue in Aβ could play an important role in 
free radical and oxidative stress generation.[2,63,65]  The tyrosine-10 residue is also an 
easy target of oxidation in the protein.[2,63]  Studies by Murakami et al. have shown that 
the oxidation of tyrosine-10 could be lead to oxidation of the methionine-35 residue, 
thereby contributing to the increase in free radical concentration and neurotoxicity of 
the protein.[63]  Thus, a vicious cycle between ROS and Aβ accumulation may accelerate 
the progression of AD. 
1.6   Spectroscopic Techniques Used 
Spectroscopic techniques are frequently utilized for analysis of biological 
samples, such as proteins.  Different forms of spectroscopy instrumentation were 
implemented throughout this study.  For Aβ, Thioflavin T (ThT) assays are commonly 
used to monitor fibril formation.  In order to observe the secondary structure, two 
different forms of spectroscopy are commonly used, circular dichroism (CD) and deep 
ultraviolet resonance Raman (dUVRR).   
The ThT assay is a fluorescence based method that can monitor the formation of 
Aβ fibrils in solution over time.  The fluorophore selectively binds to β-sheet fibrils 
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(Figure 1.4) causing it to fluoresce.[67]  The assay confirms the presence of cross-β-sheet 
structure, which is only present in amyloid fibrils.   
 
Figure 1.4:  ThT binds in the grooves of β-sheet fibrils increasing fluorescence.  
CD involves illuminating samples with circularly polarized light and then 
measuring the difference in absorption of left and right polarized light.[68] Depending on 
the secondary structure of the protein and the dihedral angles that correspond with the 
structure, the light will be absorbed differently producing characteristic CD spectra as 
seen in Figure 1.5. If the protein is lacking defined structure and is disordered, a strong 
minimum at 197 nm and a slight maximum at 217 nm will be observed. For a β-sheet 
structured protein, the spectrum is nearly flipped with a strong minimum at 217 nm and 
a slight maximum at 197 nm.  From this, classification of secondary structure was 
obtained as well as the changes in the structure over time.  
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Figure 1.5:  CD spectra of secondary structure seen in Aβ aggregation; disordered structure 
(grey) with a negative minimum at 197 nm and a slight positive maximum at 217 nm, and          
β-sheet (teal) with a positive minimum at 197 nm and a negative minimum at 217 nm. 
 
DUVRR is an emerging technique for the determination of secondary structure 
changes of a protein.  Raman is an inelastic scattering method in which the emitted light 
from molecules is shifted to different frequencies than the incident excitation light.[69]  
With dUVRR, the laser excites within the deep UV region and enhances the vibrational 
modes of the amide backbone, as well as aromatic side chains.[70]  DUVRR spectra of 
proteins have four protein backbone associated amide bonds; amide I (C=O stretching) 
at 1650-1680 cm-1, amide II (C-H/N-H in phase stretching/bending) at 1480-1560 cm-1, 
amide III (C-H/N-H out of phase stretching/bending) at 1240-1315cm-1, and amide S 
(coupled C-H/N-H bending) at 1350-1400 cm-1, as seen in Figure 1.6.[71] Intensity 
changes in these regions signify changes in secondary structure.  When a protein 
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changes from disordered to β-sheet, there are not typically high intensity changes in the 
amide modes. There can be shift in the amide S mode when transitioning between these 
two structures as well as slight intensity changes in amide I. There can also be changes 
in the environment of the aromatic residues of the protein.  Aβ contains tyrosine (Y) and 
phenylalanine (F).  The Y1 tyrosine modes are at 820 and 858 cm-1 and the Y9a, Y7a, and 
Y8b tyrosine modes are present at 1191, 1213, and 1608 cm-1, respectively.[72]  The 
phenylalanine modes are represented by the F12 mode at 1008 cm-1, F mode at 1191 
and 1213 cm-1, and F8b and F8a modes at 1586 and 1608 cm-1, respectively.[72]  With the 
use of these different spectroscopic techniques, the impact of polyphenols on the 
aggregation of Aβ can be determined.   
 
Figure 1.6:  Amide and aromatic modes present in a protein dUVRR spectrum.  
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Chapter II: Increasing Ring Substituents Decreases β-sheet Formation 
 
2.1   Abstract 
  
Stilbenoids have common structural components consisting of two phenolic rings 
with hydroxyl group substituents and a chain linker between the rings.  Hydroxyl group 
substituents on the polyphenolic rings not only facilitate hydrogen bonding with the 
protein backbone but also provide antioxidant properties.  The antioxidant capacity 
increases with the number of substituents. This study investigated the ability of 
stilbenoids, differing in the number of hydroxyl substituents to prevent β-sheet fibril 
formation. The polyphenols diethylstilbestrol, resveratrol, and piceatannol are 
structurally similar, differing in the number of hydroxyl group substituents, having two, 
three, and four, respectively. It was found that with increasing number of hydroxyl ring 
substituents on the polyphenols, the protein remained more disordered and formed 
smaller amounts of β-structure. Diethylstilbestrol, with only two ring substituents, did 
not prevent formation of β-sheet structure, which could in turn lead to the formation of 
fibrillar plaques in the brain.  
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2.2  Introduction 
 
Hydroxyl group substituents on polyphenolic rings allow for essential binding to 
the proteins through hydrogen bonding of the polyphenol to the amide rich backbone of 
the proteins.[1-3]  Studies have shown that greater numbers of hydroxyl groups on 
polyphenols, is correlated with higher the antioxidant activity.[4] Ono et al. compared 
four flavonoid compounds (myricetin, morin, quercetin, and kaempferol ) that have 
similar structures and differ only in the numbers of hydroxyl substituents.  It was found 
that decreasing the number of hydroxyl substituents decreased the anti-amyloidogenic 
and fibril-destabilizing activity of the polyphenol.[4]  
This study sought to determine the effect of the number of hydroxyl substituents 
on stilbenoids compounds, on their ability to prevent β-sheet fibril formation. The 
polyphenols diethylstilbestrol, resveratrol, and piceatannol have two, three, and four 
hydroxyl substituents on their rings, respectively. They each have a 2-atom carbon chain 
between the two rings allowing for a conjugated double bond system in the molecule.   
Piceatannol is a naturally occurring stilbenoids found in plants such as Japanese 
knotweed, as well as in fruits including many grape families. [5] Figure 2.1 shows the 
structure of the first polyphenol analyzed, piceatannol.  
 
Figure 2.1:  Structure of piceatannol. 
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 Resveratrol is found in many fruits, such as grapes, blueberries, and cranberries, 
and is famous for its presence in red wines.[6]  Resveratrol, shown in Figure 2.2, has one 
less hydroxyl group substituent than piceatannol resulting in a diminished antioxidant 
potency.  
 
Figure 2.2:  Structure of resveratrol. 
Diethylstilbestrol was first synthesized to mimic estrogen and was prescribed to 
pregnant woman in the mid-1900’s to aid in pregnancy complications.[7] In the early 
1970’s, diethylstilbestrol was found to be an endocrine disruptor, classified as a 
carcinogen, and ultimately prohibited.[7]  Diethylstilbestrol, shown in Figure 2.3, has the 
least number of hydroxyl substituents of the three compounds with only two, one on 
each ring, further lessening its antioxidant potency.   
 
Figure 2.3:  Structure of diethylstilbestrol. 
The aim of this study was to investigate how the number of hydroxyl group 
substituents on stilbenoids affects the aggregation of Aβ.    
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2.3   Materials and Methods 
2.3.1    Materials 
A(1-42)  (>95% pure) was purchased from Atlantic Peptides (Scarborough, ME).  
Ethanol and sodium perchlorate were purchased from Sigma-Aldrich (St. Louis, MO) and 
used without further purification. Sodium phosphate monobasic, sodium phosphate 
dibasic, sodium chloride, and cyclohexane were purchased from Fisher Scientific 
(Pittsburgh, PA).  Resveratrol, piceatannol, and diethylstilbestrol were purchased from 
Sigma-Aldrich (St. Louis, MO).  
2.3.2   Amyloid- β (1-42) Protein Preparation 
Aβ (1-42) (M.W. 4512.3 kDa) was dissolved in 10 mM sodium phosphate buffer, 
20 mM NaCl, pH 7.4, sonicated for 10 min in an ice bath and centrifuged for 30 minutes 
at 14,000 rcf and 4⁰C (Centrifuge 5804 R, Eppendorf AG, Hamburg Germany).  The 
concentration was estimated using the extinction coefficient of tyrosine, which is 1,280 
M-1cm-1 at 280 nm using a Varian Cary Bio 50 UV-Vis spectrophotometer (Varian, Palo 
Alto, CA)[8].  Peptide concentrations ranged from 70-80 μM and were normalized in all 
the spectral processing. Aβ was prepared and incubated at 37oC over a 12-day time 
period. During this time, samples were analyzed every four days by CD and on Day 0 and 
Day 12 by dUVRR spectroscopy.  Stock solutions of each polyphenolic compound were 
prepared in ethanol at a concentration of 5 mM.  Polyphenolic compounds were then 
added to the protein solution for a final concentration of 25 μM.  For dUVRR 
spectroscopy, sodium perchlorate was added to the sample as an internal intensity 
standard at a final concentration of 50 mM.   
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2.3.3   Circular Dichroism (CD)  
A Jasco J-815 CD Spectropolarimeter (Jasco, Easton, MD) was used to collect CD 
spectra in the range of 190-250 nm.  A scan speed of 50 nm/min with a response time of 
4 sec was used.  Five spectra were averaged for each sample.  A 1 mm optical path 
length quartz cuvette (Hellman, Plainview, NY) was employed for all measurements.  
2.3.4   Deep Ultraviolet Resonance Raman (dUVRR)  
The dUVRR instrument has been described previously by Wang et al. [8] Briefly, 
UV light was generated using the fourth harmonic of a tunable 4 kHz frequency 
quadrupled Ti:Sapphire laser (Coherent Inc., Santa Clara, CA), which was pumped by a 
diode-pumped frequency doubled Nd:YLF laser (Coherent Inc., Santa Clara, CA).  An 
excitation wavelength of 197 nm was employed for all measurements and the average 
power at the sample was attenuated to c.a. 500 μW to prevent sample degradation.  
The excitation light was directed towards the sample stream guided by two Nitinol 
wires. The sample was kept under N2 gas to eliminated ambient oxygen, as O2 has a 
feature at 1550 cm-1.  Spectra were calibrated using a cyclohexane spectrum and 50 mM 
sodium perchlorate was used as an internal intensity standard.  
2.3.5   Data Analysis  
Data analysis was carried out in the MATLAB R2016b (MathWorks, Natick, MA) 
environment.  For all dUVRR spectra, the background buffer spectrum was subtracted 
and cosmic spikes were removed using an in-house cosmic ray removal algorithm.  A 
nonlinear least-squares (NLLS) algorithm was used to fit each spectrum with a series of 
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Gaussian/Lorentzian bands, which approximate the Voigt line shape, as described 
previously.[9] All dUVRR spectra are the average of triplicate trials.  
The amide I mode was deconvoluted into two peaks at 1657 and 1670 cm-1. The 
amide II mode was centered at 1559 cm-1, and the amide S mode was centered 1400 
cm-1. The amide III mode was deconvoluted into three bands at 1244, 1275, and 1311 
cm-1. Aβ has one tyrosine and three phenylalanines. It is likely that the tyrosine mode at 
1263 cm-1 also contributes to the intensity of the amide III bands. Other tyrosine modes 
that show up in the dUVRR spectrum of Aβ include the fermi doublet (Y1) fitted at 820 
and 858 cm-1. The band at 820 cm-1 is about 10 cm-1 lower than expected, which is likely 
due to the high noise level at this region. The fitted peak at 1191 cm-1 is an overlapping 
phenylalanine and tyrosine mode (F/Y9a) that arises from C-H bending. The ring 
stretching modes of phenylalanine and tyrosine are also overlapped with combined 
bonds at 1213 and 1608 cm-1. The feature at 936 cm-1 is from perchlorate, which was 
added as an internal intensity standard. A sharp feature at 1441 cm-1 is present in some 
spectra because TFA was added as a counter ion during the purification of early batches 
of the synthetic Aβ. The counter ion was later replaced by hydrochloride to remove this 
peak from the spectra. Difference spectra were created by subtraction of dUVRR spectra 
of Aβ from spectra of samples treated with polyphenols at each time point (Days 0 and 
12). The difference spectra were multiplied by ten to better visualize the differences. 
Further difference spectra were created by subtraction of Day 0 dUVRR spectra from 
Day 12 dUVRR spectra to visualize the structural impact of the polyphenols made on the 
protein over time in the aromatic regions.  
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All CD spectra were averaged and the background buffer spectrum was 
subtracted from the raw data.  The mean residue ellipticity (θMRE) was calculated using 
Equation 1 with θ being the raw ellipticity from the measurement (degrees), MW being 
the molecular weight of the protein (g/mol), n being the number of protein residues, d 
being the path length of the cell (cm), and C being the concentration of the sample 
(M).[8-10]  All spectra are averaged spectra of triplicate trials.  
Equation 1:       
2.4   Results  
 
2.4.1   Aβ Untreated  
 
Figure 2.4 shows the CD spectra of Aβ during the 12-day incubation period. 
Initially on Day 0, the protein is disordered in structure, as indicated by the minimum at 
197 nm. Over time, this feature decreases in intensity and another minimum is formed 
at 217 nm, indicative of β-sheet formation.  
 
Figure 2.4:  CD spectra of Aβ42 during a 12-day incubation period; Day 0 (black), Day 4 (blue), 
Day 8 (red), and Day 12 (green).  
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2.4.2   Piceatannol  
Figure 2.5 shows the CD spectra of Aβ treated with piceatannol during the 12-
day incubation period. Initially on Day 0, the protein is disordered in structure, as 
indicated by the minimum at 197 nm. There is a slight loss of intensity at 197 nm on Day 
4 but over time, the protein remains in a disordered state with no additional changes in 
structure. Thus, the addition of piceatannol prevents the protein from forming β-sheet 
structure. 
 
Figure 2.5:  CD spectra of Aβ42 treated with piceatannol during a 12-day incubation period; Day 
0 (black), Day 4 (blue), Day 8 (red), and Day 12 (green).  
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Figure 2.6 shows the dUVRR spectra of the Aβ protein treated with piceatannol 
on Day 0 when it was prepared and almost two weeks later on Day 12. The spectra were 
deconvoluted with each peak representing an amide or aromatic mode in the protein. 
Over time, there is no observable change in the spectra, however key differences are 
highlighted through difference spectra shown later.  
 
Figure 2.6:  Deconvoluted dUVRR spectra of Aβ42 treated with piceatannol on Days 0 and 12 
(purple).  Deconvolution of the individual amide and aromatic modes was performed and those 
peaks are shown under each spectrum.  
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Figure 2.7 shows the overlaid spectra of untreated Aβ and Aβ treated with 
piceatannol on Days 0 and 12. Differences are seen in amide III at 1244 cm-1, amide S at 
1400 cm-1, and amide II at 1559 cm-1 which are stronger in the treated versus untreated 
spectrum on Day 12. Differences in the Y and F modes are seen predominantly in the Y 
modes at 820 and 858 cm-1, and the Y/F modes at 1191, 1586, and 1608 cm-1.   
 
 
Figure 2.7:  DUVRR spectra of Aβ42 (black) overlaid with Aβ42 treated with piceatannol (purple) 
on Days 0 and 12.   
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Figure 2.8 shows the difference between the untreated Aβ protein spectrum and 
the piceatannol-treated Aβ spectrum on Days 0 and 12. The difference spectra on Days 
0 and 12 highlight that the amide modes are stronger in the dUVRR spectra of the 
treated samples. Modes associated with tyrosine at 858, 1191, 1213, and around 1608 
cm-1 are increased in intensity in the dUVRR spectra of the treated samples. 
Interestingly, modes associated with phenylalanine at 1008, 1586, and 1608 cm-1 are 
decreased in intensity.    
 
Figure 2.8: DUVRR difference spectra of the deconvoluted peaks of untreated Aβ42 and Aβ42 
treated with piceatannol on Day 0 and Day 12.  The amide modes are shown in blue and the 
aromatic modes are shown in green.  
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2.4.3   Resveratrol  
 
Figure 2.9 shows the CD spectra of Aβ treated with resveratrol during the 12-day 
incubation period. Initially on Day 0, the CD spectrum indicates that the protein is 
disordered in structure as indicated by the strong minimum at 197 nm.  The intensity of 
the minimum at 197 nm decreases with increasing incubation time, suggesting that the 
protein is changing structure. A small minimum begins to form at 217 nm by day 4, 
which is indicative of β-sheet structure. Addition of resveratrol does not prevent the Aβ 
from forming β-sheet structure during incubation. Resveratrol may slow the formation 
of β-sheet structure, but ultimately it does not prevent aggregation.  
 
Figure 2.9:  CD spectra of Aβ42 treated with resveratrol during a 12-day incubation period; Day 0 
(black), Day 4 (blue), Day 8 (red), and Day 12 (green).  
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Figure 2.10 shows the dUVRR spectra of the Aβ protein treated with resveratrol 
on Days 0 and 12. The spectra were deconvoluted in to a series of peaks that represent 
the amide and aromatic modes of the protein. Over the 12-day incubation period, there 
is no pronounced change in the spectra, however key differences are highlighted in the 
difference spectra shown later. 
 
Figure 2.10:  Deconvoluted dUVRR spectra of Aβ42 treated with resveratrol on Days 0 and 12 
(pink).  Deconvolution of the individual amide and aromatic modes was performed and those 
peaks are shown under each spectra.  
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Figure 2.11 shows the overlaid dUVRR spectra of untreated Aβ and Aβ treated 
with resveratrol on Days 0 and 12. There are more differences between the Day 0 
spectra than the Day 12 spectra. The CD spectra show that initially the protein is 
disordered, but it eventually forms β-sheet structure. The similarity of the Day 12 
spectra suggest that any differences in structure initially between the two treatments 
are likely gone after 12 days of incubation.    
 
Figure 2.11:  DUVRR spectra of Aβ42 (black) overlaid with Aβ42 treated with resveratrol (pink) on 
Days 0 and 12.   
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Figure 2.12 shows the difference spectra of the untreated Aβ protein and 
resveratrol-treated Aβ on Days 0 and 12. Initially there is a large difference in the 
intensity of the amide modes but this difference is reduced over time, likely due to the 
fact resveratrol does not prevent formation of β-sheet structure. The aromatic modes 
associated with tyrosine are stronger in the dUVRR spectra of Aβ treated with 
resveratrol but the phenylalanine modes at 1008 cm-1 is not.   
 
Figure 2.12:  DUVRR difference spectra of the deconvoluted peaks of untreated Aβ42 and Aβ42 
treated with resveratrol the untreated Aβ on Day 0 and Day 12.  The amide modes are shown in 
blue and the aromatic modes are shown in green.  
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2.4.4   Diethylstilbestrol 
 
Figure 2.13 shows the CD spectra of diethylstilbestrol-treated Aβ during the 
incubation period. Initially on Day 0, the CD spectrum indicates that the protein is 
largely disordered as indicated by the minimum at 197 nm. However, the CD spectrum 
quickly loses the negative feature at 197 nm and develops the characteristic β-sheet 
associated minimum at 217 nm. After Day 4, the CD spectrum remains stable indicating 
the structure of the protein remains unchanged for the rest of the incubation period.  
 
Figure 2.13:  CD spectra of Aβ42 treated with diethylstilbestrol during a 12-day incubation 
period; Day 0 (black), Day 4 (blue), Day 8 (red), and Day 12 (green).  
 
 
 
 
 
 
 38 
Figure 2.14 shows the dUVRR spectrum of the Aβ protein treated with 
diethylstilbestrol on Days 0 and 12.   With respect to the internal intensity standard 
perchlorate, the entire spectrum decreases in intensity. A decrease in overall intensity 
may be associated with formation of insoluble β-sheet oligomers.  
 
Figure 2.14:  Deconvoluted dUVRR spectra of Aβ42 treated with diethylstilbestrol on Day 0 and 
Day 12 (blue).  Deconvolution of the individual amide and aromatic modes was performed and 
those peaks are shown under each spectra.  
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Figure 2.15 shows the overlaid spectra of untreated Aβ42 and Aβ42 treated with 
diethylstilbestrol on Days 0 and 12. The most pronounced differences between the 
untreated and diethylstilbestrol-treated Aβ spectra are in the amide III and amide I 
regions. Differences in the aromatic modes of Y at 820 cm-1 and F at 1586 and 1608 cm-1 
were also apparent. The spectrum of untreated Aβ also has a TFA peak that is not 
present in the diethylstilbestrol-treated sample spectrum, as the counter ion for the 
protein was changed to hydrochloride which does not have a feature in dUVRR spectra.   
 
Figure 2.15: DUVRR spectra of Aβ42 (black) overlaid with Aβ42 treated with diethylstilbestrol 
(blue) on Days 0 and 12.  
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Figure 2.16 shows the difference spectra for the untreated Aβ protein and 
diethylstilbestrol-treated Aβ protein on Days 0 and 12.  The amide II band at 1244 cm-1 is 
more intense suggesting the treated sample may have more β-sheet structure than the 
untreated sample initially. Interestingly, the amide I band is less intense. The aromatic 
bands are also decreased in intensity.     
 
Figure 2.16:  DUVRR difference spectra of the deconvoluted peaks of untreated Aβ42 and Aβ42 
treated with diethylstilbestrol on Day 0 and Day 12.  The amide modes are shown in blue and the 
aromatic modes are shown in green.  
 
2.5   Discussion 
 
The number of hydroxyl substituents on the rings of the stilbenoids used to treat 
Aβ samples appears to be positively correlated with the polyphenol’s ability to prevent 
β-sheet formation. Specifically, more substituents on the rings of the stilbenoid traps 
the peptide in a disordered state as confirmed by CD.  On Day 0, each of the polyphenol-
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treated samples are disordered as evidenced by the strong negative feature at 197 nm 
in their CD spectra. By Day 4, the negative intensity at 197 nm is reduced in CD spectra 
of all samples, but to differing degrees. The piceatannol-treated sample remained 
largely disordered, while the sample treated with resveratrol has an observable amount 
of β-sheet structure. Samples treated with diethylstilbestrol lost their disordered 
structure completely by Day 4 and formed β-sheet structure.   
As the number of hydroxyl substituents decrease, there is a trend in the effect 
on the aromatic modes as seen in Figure 2.17. The phenylalanine mode at 1008 cm-1 
was most intense in the dUVRR spectrum of Aβ treated with piceatannol, which has the 
greatest number of hydroxyl substituents. As the number of hydroxyl substituents 
decreases, the intensity of the 1008 cm-1 band decreased. The overlapped ring 
stretching Y/F mode at 1213 cm-1 was increased in dUVRR spectra of samples treated 
with piceatannol or resveratrol but decreased in samples treated with diethylstilbestrol.  
As the number of substituents on the rings of the stilbenoids decrease, aromatic 
modes mainly decrease in intensity.  As the number of substituents increase, there 
appears to be less interaction between the stilbenoid and the aromatic residues of the 
protein. Decreasing the polarity of the chain linker may also yield a stronger interaction 
between the polyphenol and the aromatic residues of the protein. This is seen in Figure 
2.17 where the aromatic modes are most perturbed in the dUVRR spectra of samples 
treated with diethylstilbestrol. Decreasing the number of substituents, reduces the 
polarity of the polyphenol. This may be allowing for more pi-stacking interactions with 
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the protein yielding greater changes in the aromatic bands than when more hydroxyl 
groups are present on the ring.  
 
Figure 2.17:  Changes over the 12-day incubation period in the individual aromatic modes of the 
dUVRR spectra. Diethylstilbestrol (blue), resveratrol (pink), and piceatannol (purple) are shown.  
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Chapter III: Increasing Chain Linker Polarity Increases β-sheet Formation 
 
3.1   Abstract 
 
Diaryl polyphenolic compounds have common structural components consisting 
of two phenolic rings with hydroxyl group substituents and a chain linker between the 
rings. The chain between the two phenol rings can vary significantly both in length and 
atom makeup, affecting the potency of the polyphenol.  Flavonoid compounds do not 
contain a chain linker and understanding how the chain linker can affect the activity of 
non-flavonoid compounds is imperative.  The aromatic rings of polyphenols are 
important for their binding to proteins and effects on protein aggregation.  The type of 
linker between the aromatic rings of diaryl polyphenols is also important because it 
could affect Aβ binding and aggregation. The diaryl polyphenols nordihydroguaiaretic 
acid, curcumin, and rosmarinic acid have increasing polarity, respectively, in the chain 
linker between the phenolic rings. Each of these polyphenols has four ring substituents 
and 4 - 6 atoms in their chain linker. It this study, it was found that with increasing 
polarity of the linker, the polyphenol-treated Aβ sample had a greater tendency to form 
a β-structure.  Thus, in order to maintain Aβ in a disordered structure (non-fibrillar), the 
linker between the phenol rings should be of low polarity. A polar linker leads to a 
reduction in disordered content and an increase in β-sheet structure in the protein.  
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3.2   Introduction   
 
The chain linker between the two phenol rings can vary significantly both in 
length and atom makeup, and has an important impact on how the polyphenols will 
metabolize and behave.[1-2]  It is suggested that the optimum chain length for inhibiting 
amyloid formation between the rings should be 2-6 atoms long.[3]  Studies have shown 
that diaryl polyphenols such as curcumin, are better than flavonoids at inhibiting Aβ’s 
amyloidogenic activity, possibly due to the type of chain linker between the aromatic 
rings.[1-2] 
The aromatic rings are important for polyphenol binding to proteins and for 
inhibiting protein aggregation.  The aromatic rings of polyphenols participate in 
hydrophobic interactions with proteins that can interrupt endogenous hydrophobic 
interactions within the protein. The endogenous interactions promote aggregation of Aβ 
by maintaining its stability and orienting the protein for self-assembly of organized 
structures.[ 3, 4-9] The rings of polyphenols have the necessary planarity to bind to the 
protein in the hydrophobic groove, interrupt the π stacking, and preventing aggregation 
by intercalating within the β-sheets.[1, 4, 10-11]  The chain linker polarity will affect the 
polyphenol’s overall polarity and its ability to disrupt hydrophobic interactions 
necessary for protein aggregation.  
The polyphenols nordihydroguaiaretic acid, curcumin, and rosmarinic acid have 
increasing polarity, respectively, within the chain linker region between their phenolic 
rings. Each of these polyphenols have four ring substituents and 4 - 6 atoms in their 
chain linker.  
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Nordihydroguaiaretic acid is a plant based polyphenol found in the leaves of a 
desert shrub, the creosote bush and is valued for its anti-inflammatory effects.[12]  
Nordihydroguaiaretic acid, shown in Figure 3.1, is the least polar of the polyphenols 
evaluated in this study. It has four atoms in the chain linker between the rings with two 
methyl substituents off the second and third carbons. It has a total of four hydroxyl 
groups on the rings as well.   
 
Figure 3.1:  Structure of nordihydroguaiaretic acid. 
Curcumin is the principal curcuminoid found in turmeric and has not only been 
used as a spice, but for its anticancer and anti-inflammatory effects as well.[13]  
Curcumin, shown in Figure 3.2, is more polar than nordihydroguaiaretic acid, but less 
polar than rosmarinic acid. It has five atoms in the chain linker between the rings with 
one hydroxyl substituent off the second carbon and a ketone off the fourth carbon. It 
has a total of two hydroxyl groups on the rings as well as two ether groups.  
 
Figure 3.2:  Structure of curcumin. 
 
Rosmarinic acid is commonly found in many spices such as sage, mint, thyme, 
basil, and rosemary where it developed its name.[14] Rosmarinic acid, shown in Figure 
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3.3, is the most polar of the three polyphenols evaluated. It has six atoms in the chain 
linker between the rings with an ester and carboxylic acid on the third and fourth 
carbons, respectively.  
 
Figure 3.3:  Structure of rosmarinic acid. 
This study aims to discover how the polarity of the chain linker of polyphenols 
can affect Aβ aggregation and β-sheet formation over time.  
3.3   Materials and Methods   
3.3.1    Materials 
A(1-42)  (>95% pure) was purchased from Atlantic Peptides (Scarborough, ME).  
Ethanol and sodium perchlorate were purchased from Sigma-Aldrich (St. Louis, MO) and 
used without further purification. Sodium phosphate monobasic, sodium phosphate 
dibasic, sodium chloride, and cyclohexane were purchased from Fisher Scientific 
(Pittsburgh, PA).  Rosmarinic acid and nordihydroguaiaretic acid were purchased from 
Sigma-Aldrich (St. Louis, MO) and curcumin was purchased from Acros Organics 
(Pittsburgh, PA).  
3.3.2   Spectroscopic Measurements and Data Analysis 
The amyloid-β (1-42) protein was prepared and characterized as described in 
Chapter 2, section 2.3.2. Circular dichroism (CD) and deep-ultraviolet resonance Raman 
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(dUVRR) were collected, processed, and analyzed as described in Chapter 2, sections 
2.3.3-2.3.5. 
3.4   Results  
 
3.4.1   Aβ Untreated  
 
Figure 3.4 shows the CD spectra of Aβ during the 12-day incubation period. 
Initially on Day 0, the protein is a disordered in structure, as indicated by the minimum 
at 197 nm. Over time, this feature decreases in intensity and another minimum forms at 
217 nm indicative of β-sheet formation.  
 
Figure 3.4:  CD spectra of Aβ42 during a 12-day incubation period; Day 0 (black), Day 4 (blue), 
Day 8 (red), and Day 12 (green).  
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3.4.2   Nordihydroguaiaretic Acid 
Figure 3.5 shows the CD spectra of nordihydroguaiaretic acid-treated Aβ during 
the incubation period. Similar to the untreated Aβ sample, on Day 0, the treated protein 
is a disordered in structure, as indicated by the minimum at 197 nm. There is a slight 
loss of intensity at 197 nm on Day 4 but over time, the structure of the treated protein 
remains stable and disordered.  
 
Figure 3.5:  CD spectra of Aβ42 treated with nordihydroguaiaretic acid during a 12-day 
incubation period; Day 0 (black), Day 4 (blue), Day 8 (red), and Day 12 (green).  
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Figure 3.6 shows the Aβ protein treated with nordihydroguaiaretic acid on Days 
0 and 12. The most noteworthy difference is the peak at 1295 cm-1.  This extra peak is 
attributed to the stretching of the hydroxyl groups on the rings of the polyphenol itself.  
Over time, there is no visible change between the Day 0 and Day 4 dUVRR spectra other 
than this peak from nordihydroguaiaretic acid. After 12 days, this peak disappears due 
to the oxidation of the polyphenol. The hydroxyl groups donate a hydrogen to the 
protein which could be crucial in preventing protein aggregation.  Observing this peak 
on Day 0 and not on Day 12 confirms that the polyphenol is undergoing oxidation.  
 
Figure 3.6:  Deconvoluted dUVRR spectra of Aβ42 treated with nordihydroguaiaretic acid on 
Days 0 and 12 (blue).  Deconvolution of the individual amide and aromatic modes was performed 
and those peaks are shown under each spectra.  
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Figure 3.7 shows the overlaid spectra of untreated Aβ and Aβ treated with 
nordihydroguaiaretic acid on Days 0 and 12. The most pronounced difference between 
the untreated and treated Aβ dUVRR spectra is the peak at 1295 cm-1 from the 
polyphenol. Other differences include a slight increase in the intensity of the F/Y modes 
at 1586 and 1608 cm-1 as well as the Y mode at 858 cm-1 for the treated sample. 
 
Figure 3.7:  DUVRR spectra of Aβ42 (black) overlaid with Aβ42 treated with nordihydroguaiaretic 
acid (blue) on days 0 and 12.   
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Figure 3.8 shows the differences between the untreated Aβ protein and the 
nordihydroguaiaretic acid-treated Aβ dUVRR spectra on Days 0 and 12. The largest 
difference between the Day 0 spectra is in the amide III region, which is primarily due to 
the loss of the 1295 cm-1 peak from the polyphenol. On Day 0, tyrosine associated 
modes appear to be stronger in the spectrum of the treated Aβ sample, but the 
phenylalanine mode at 1008 cm-1 appears to have lower intensity. By Day 12, the 
differences in the aromatic modes have diminished.  
 
Figure 3.8:  DUVRR difference spectra of the deconvoluted peaks of Aβ42 treated with 
nordihydroguaiaretic acid and the untreated Aβ42 on Day 0 and Day 12.  The amide modes are 
shown in blue and the aromatic modes are shown in green.  
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3.4.3   Curcumin 
Figure 3.9 shows the CD spectra of curcumin-treated Aβ during the incubation 
period. Initially on Day 0, the curcumin-treated protein is disordered in structure, as 
indicated by the minimum at 197 nm.  Although there is a slight loss of intensity at 197 
nm after each time point, the treated protein remains in disordered state.  
 
Figure 3.9:  CD spectra of Aβ42 treated with curcumin during a 12-day incubation period; Day 0 
(black), Day 4 (blue), Day 8 (red), and Day 12 (green).  
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Figure 3.10 shows the dUVRR spectra of the Aβ protein treated with curcumin on 
Days 0 and 12. Difference spectra are needed to observe any changes that are occurring. 
The F/Y modes at 1589 and 1611 cm-1 are visibly different between Days 0 and 12.  
 
Figure 3.10:  Deconvoluted dUVRR spectra of Aβ42 treated with curcumin on Days 0 and 12 
(green).  Deconvolution of the individual amide and aromatic modes was performed and those 
peaks are shown under each spectra.  
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Figure 3.11 shows the overlaid spectra of curcumin treated and untreated Aβ 
samples on Days 0 and 12. The differences between the dUVRR spectra of the untreated 
and treated Aβ samples on Day 0 are predominately limited to the aromatic ring modes 
at 1213, 1589, and 1611 cm-1. On Day 12, the Aβ sample differs from the curcumin-
treated sample spectrum in the amide I, II, and III modes.  Overall, the amide I, II, and III 
modes are less intense.  
 
Figure 3.11:  DUVRR spectra of Aβ42 (black) overlaid with Aβ42 treated with curcumin (green) on 
Days 0 and 12.   
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Figure 3.12 shows the difference between the untreated Aβ protein and the 
curcumin treated Aβ dUVRR spectra on Days 0 and 12. Initially on Day 0, the fitted 
aromatic modes are more intense in the spectrum of the treated sample. By Day 12, 
differences in the amide regions are observed due to differences in the structure of the 
protein between the untreated and curcumin-treated samples.  
 
Figure 3.12:  DUVRR difference spectra of the deconvoluted peaks of Aβ42 treated with curcumin 
and the untreated Aβ42 on Day 0 and Day 12.  The amide modes are shown in blue and the 
aromatic modes are shown in green.  
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3.4.4   Rosmarinic Acid 
 
Figure 3.13 shows the CD spectra of rosmarinic acid-treated Aβ during the 12-
day incubation period. On Day 0, the protein is disordered in structure, as indicated by 
the minimum at 197 nm. Although the protein remains disordered in structure over 
time, there is a loss of intensity at 197 nm, and a minimum at 217 nm begins to develop.  
 
Figure 3.13:  CD spectra of Aβ42 treated with rosmarinic acid during a 12-day incubation period; 
Day 0 (black), Day 4 (blue), Day 8 (red), and Day 12 (green).  
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Figure 3.14 shows the dUVRR spectra of the Aβ protein treated with rosmarinic 
acid on Days 0 and 12. There is a visible loss of intensity in the amide III mode at 1275 
cm-1 and the amide I mode at 1654 and 1678 cm-1. There are also changes in the 
aromatic modes at 1586 and 1608 cm-1.  
 
Figure 3.14:  Deconvoluted dUVRR spectra of Aβ42 treated with rosmarinic acid on Days 0 and 
12 (red).  Deconvolution of the individual amide and aromatic modes was performed and those 
peaks are shown under each spectra.  
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Figure 3.15 shows the overlaid spectra of Aβ treated with rosmarinic acid protein 
and the untreated protein sample on Days 0 and 12. The most pronounced difference 
between the untreated and treated Aβ spectra is the peak in the amide III region around 
1295 cm-1.  Loss of intensity in this region without a concurrent decrease in the amide III 
intensity at 1244 cm-1, may suggest a greater proportion of β-structure in the samples 
treated with rosmarinic acid. The strong feature at 1441 cm-1 arises from TFA, as 
mentioned earlier. Addition of rosmarinic acid also results in a decrease in the amide I 
mode at 1657 and 1667 cm-1 and the F/Y modes at 1586 and 1608 cm-1.  
 
Figure 3.15:  DUVRR spectra of Aβ42 (black) overlaid with Aβ42 treated with rosmarinic acid 
(red) on Days 0 and 12.  
  
 
 
 
 60 
Figure 3.16 shows the differences between the dUVRR spectra of the untreated 
Aβ protein and rosmarinic acid-treated Aβ on Days 0 and 12. Initially, the differences are 
predominantly located in the amide regions. Specifically, the amide III band at 1295 cm-1 
appear lower in intensity suggesting a structural difference. By Day 12, the amide III and 
II modes are stronger in the dUVRR spectrum of the treated sample. Small differences in 
the F/Y modes at 1586 and 1608 cm-1 and the F mode at 1008 cm-1 are also observed 
upon rosmarinic acid treatment of Aβ.    
 
Figure 3.16:  DUVRR difference spectra of the deconvoluted peaks of Aβ42 treated with 
rosmarinic acid and the untreated Aβ42 on Day 0 and Day 12.  The amide modes are shown in 
blue and the aromatic modes are shown in green.  
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3.5   Discussion 
As the polarity of the polyphenolic linker increased, the Aβ protein had a greater 
tendency to form a β-structure when exposed to polyphenols. Thus more non-polar 
linkers between the phenol rings should promote disordered structure.  A more polar 
linker leads to the reduction of disordered content in Aβ and an increase in β-sheet 
structure.  This was first observed by analyzing the CD spectra of Aβ with each 
polyphenol. Each polyphenol-treated Aβ samples starts off predominantly disordered 
protein structure on Day 0.  The Day 0 CD spectra have the most intense minima at 197 
nm, which was observed throughout the 12-day incubation period.  The CD spectra of all 
the polyphenol-treated Aβ samples become less intense over time, but by differing 
amounts. The CD spectra indicate the nordihydroguaiaretic acid-treated Aβ changes 
structure only a very small amount and then the structure stabilizes. When curcumin 
was added to the sample, Aβ’s structure remained disordered, but its structure slowly 
changed throughout the 12-day incubation period. Rosmarinic acid slowed but did not 
prevent formation of β-structure.  
Previous studies have shown that when a protein goes from a disordered to β-
sheet structure, changes in the dUVRR spectrum are minimal.  There can be an overall 
loss of intensity, seen mainly in the amide modes, if aggregates form.[15] Also, a blue 
shift of the amide S mode in the dUVRR spectra can indicate β-sheet formation from 
disordered structure.[15] This shift is observed in dUVRR spectra of Aβ in the presence of 
polyphenols with linkers of increasing polarity (Figure 3.17). The Day 12 dUVRR spectra 
of Aβ with each polyphenol are stacked to show the peak shift. The 
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nordihydroguaiaretic acid-treated protein has the lowest peak maxima at 1394 cm-1, 
followed by the curcumin-treated protein at 1397 cm-1, and then the rosmarinic acid-
treated protein, which occurs at 1405 cm-1. The CD spectra of the rosmarinic acid-
treated Aβ changed the most over time.  Whereas the CD spectra of the 
nordihydroguaiaretic acid-treated Aβ remained stable, indicating the protein remained 
in a stable disordered structure over the 12-day incubation period. Thus, the dUVRR and 
CD data correlate well.  
 
Figure 3.17:  Blue shift of the amide S mode of Aβ; nordihydroguaiaretic acid (blue), curcumin 
(green), and rosmarinic acid (red) treatments.   
DUVRR spectroscopy is useful for observing protein conformational changes, but 
the aromatic modes in dUVRR spectra are also useful for monitoring changes in the 
environment of aromatic residues within a protein. The two aromatic amino acids 
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present in Aβ are Y and F. For all polyphenol-treated Aβ samples, the Y mode at 820 cm-1 
in dUVRR spectra decreased as compared to untreated Aβ samples. The Y mode at 858 
cm-1 also decreases to the greatest extent with nordihydroguaiaretic acid treatment, 
whereas the Y mode at 1608 cm-1 decreases with all of the polyphenols tested. The 
more polar the chain linker, the more dramatic the observed decrease was observed. 
Another mode that follows this polarity trend is the F mode at 1008 cm-1, for which only 
nordihydroguaiaretic acid, the least polar polyphenol, caused an increase in its intensity. 
Curcumin treatment caused a small decrease in this F mode, whereas and rosmarinic 
acid treatment caused a large decrease in the F mode intensity as compared to 
untreated Aβ. Among the polyphenols tested, the Y/F mode at 1213 cm-1 decreased the 
most dramatically when rosmarinic acid was added.  
In general, the Y modes decreased in intensity over time when Aβ has been 
treated with polyphenolic compounds. Polyphenols containing a more polar chain 
linker, i.e., curcumin and rosmarinic acid, causes decreases in the F mode intensity, 
while a nonpolar chain linker as in nordihydroguaiaretic acid caused an increase in this 
mode. Increasing the polarity of the chain linker results in a greater change in the 
environment of the aromatic residues of the protein. This is seen in Figure 3.18, where 
Aβ samples treated with rosmarinic acid seem to have the largest differences in the 
aromatic regions.  
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Figure 3.18:  Changes over the 12-day incubation period in the individual aromatic modes of the 
dUVRR spectra. Nordihydroguaiaretic acid (blue), curcumin (green), and rosmarinic acid (red) are 
shown, as well as spectra of the aromatics tyrosine (orange) and phenylalanine (grey).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65 
3.6   References  
 
1. Lakey-Beitia, J.; Berrocal, R.; Rao, K. S.; Durant, A. A., Polyphenols as therapeutic molecules in 
Alzheimer's disease through modulating amyloid pathways. Mol Neurobiol 2015, 51 (2), 466-479. 
2. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M., Potent anti-
amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the 
prevention and therapeutics of Alzheimer's disease. J Neurochem 2003, 87 (1), 172-181. 
3. Shoval, H.; Lichtenberg, D.; Gazit, E., The molecular mechanisms of the anti-amyloid effects of 
phenols. Amyloid 2007, 14 (1), 73-87. 
4. Porat, Y.; Abramowitz, A.; Gazit, E., Inhibition of amyloid fibril formation by polyphenols: 
structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol 
Drug Des 2006, 67 (1), 27-37. 
5. Gazit, E., Mechanisms of amyloid fibril self-assembly and inhibition:  Model short peptides as a 
key research tool. FEBS J 2005, 272, 5971-5978. 
6. Gazit, E., Global analysis of tandem aromatic octapeptide repeats: The significance of the 
aromatic-glycine motif. Bioinformatics 2002, 18 (6), 880-883. 
7. Porat, Y.; Mazor, Y.; Efrat, S.; Gazit, E., Inhibition of islet amyloid polypeptide fibril formation: a 
potential role for heteroaromatic interactions. Biochem 2004, 43, 14454-14462. 
8. Azriel, R.; Gazit, E., Analysis of the minimuml amyloid-forming fragment of the islet amyloid 
polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid 
formation. J Biol Chem 2001, 276 (36), 34156-24161. 
9. Hudson, S. A.; Ecroyd, H.; Dehle, F. C.; Musgrave, I. F.; Carver, J. A., (-)-Epigallocatechin-3-gallate 
(EGCG) maintains kappa-casein in its pre-fibrillar state without redirecting its aggregation 
pathway. J Mol Biol 2009, 392 (3), 689-700. 
10. Convertino, M.; Pellarin, R.; Catto, M.; Carotti, A.; Caflisch, A., 9,10-Anthraquinone hinders beta-
aggregation: how does a small molecule interfere with Abeta-peptide amyloid fibrillation? 
Protein Sci 2009, 18 (4), 792-800. 
 66 
11. Lashuel, H. A.; Hartley, D. M.; Balakhaneh, D.; Aggarwal, A.; Teichberg, S.; Callaway, D. J., New 
class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of 
pathogenesis in Alzheimer's disease. J Biol Chem 2002, 277 (45), 42881-42890. 
12. Arteaga, S.; Andrade-Cetto, A.; Cárdenas, R.  Larrea tridentate (Creosote bush), an abundant 
plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. J 
Ethnopharmacol 2005, 98 (3), 231–239.  
13. Gupta, S. C.; Kismali, G.; Aggarwal B. B. Curcumin, a component of turmeric: from farm to 
pharmacy. Biofactors 2013, 39 (1), 2-13. 
14. al-Sereiti, M. R.; Abu-Amer, K. M.; Sen, P. Pharmacology of rosemary (Rosmarinus officinalis 
Linn.) and its therapeutic potentials. Indian J Exp Biol 1999, 37 (2), 124-130. 
15. Oladepo, S. A.; Xiong, K.; Hong, Z.; Asher, S. A.; Handen, J.; Lednev, I. K. UV resonance Raman 
investigations of peptide and protein structure and dynamics. Chem Rev 2012, 112, 2604-2628.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
Chapter IV: Increasing Ring Substituents Destabilizes Pre-formed Amyloid- 
β Fibrils 
 
4.1   Abstract 
 
Stilbenoid compounds have common structural components consisting of two 
phenolic rings with hydroxyl group substituents and a chain linker between the rings.  
Hydroxyl groups on polyphenolic rings not only facilitate hydrogen bonding with the 
protein backbone, but also provide the compound with the ability to be an antioxidant.  
The antioxidant capacity increases with the number of hydroxyl substituents. This study 
investigated the ability of stilbenoid compounds differing in the number of hydroxyl 
substituents, to destabilize pre-formed Aβ fibrils. The polyphenols diethylstilbestrol, 
resveratrol, and piceatannol are structurally similar, but differ in the number of hydroxyl 
group substituents, i.e., two, three, and four, respectively. It was found that with 
increased number of hydroxyl ring substituents, pre-formed Aβ fibrils were destabilized 
more readily by the polyphenol.  
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4.2   Introduction 
 
Hydroxyl group substituents on polyphenolic rings allow for essential binding to 
the protein through hydrogen bonds from the polyphenol to the amide rich backbone of 
the protein.[1-3]  Studies have shown that the more hydroxyl groups, the higher the 
antioxidant activity.[4] Ono et al. compared four flavonoid compounds (myricetin, morin, 
quercetin, and kaempferol ) that have similar structures and differ only in the numbers 
of hydroxyl substituents.  It was found that decreasing the number of hydroxyl 
substituents decreased the anti-amyloidogenic and fibril-destabilizing activities of the 
polyphenol.[4] Polyphenols can act on Aβ aggregation at three different stages; initial 
formation of fibrils, extension of formed fibrils, and destabilization of pre-formed Aβ 
fibrils. A polyphenol may act at only one of these stages or possibly at all three.[4,5]    
In Chapter 2, it was shown that increasing the number of hydroxyl substituents 
on polyphenols incubated with Aβ retarded structural changes that promote 
progression from a disordered to β-sheet structure.  Using the same polyphenols as in 
Chapter 2 (i.e., diethylstilbestrol, resveratrol, and piceatannol), their effect on 
destabilization of pre-formed Aβ fibrils was assessed. The polyphenols diethylstilbestrol, 
resveratrol, and piceatannol shown in Figure 4.1 have an increasing numbers of hydroxyl 
substituents on their rings, having two, three, and four, respectively.  They each have a 
2-atom carbon chain between the two rings allowing for a conjugated double bond 
system. This study aims to examine how the number of hydroxyl group substituents 
affects the polyphenol’s ability to destabilize pre-formed Aβ fibrils.  
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a b c 
Figure 4.1: Structures of piceatannol (a), resveratrol (b), and diethylstilbestrol (c).      
4.3   Materials and Methods 
4.3.1    Materials 
A(1-42)  (>95% pure) was purchased from Atlantic Peptides (Scarborough, ME).  
Ethanol and sodium perchlorate were purchased from Sigma-Aldrich (St. Louis, MO) and 
used without further purification. Sodium phosphate monobasic, sodium phosphate 
dibasic, sodium chloride, and cyclohexane were purchased from Fisher Scientific 
(Pittsburgh, PA).  Thioflavin T, resveratrol, piceatannol, and diethylstilbestrol were 
purchased from Sigma-Aldrich (St. Louis, MO).  
4.3.2   Amyloid- β (1-42) Protein Preparation 
Aβ (1-42) (M.W. 4512.3 kDa) was dissolved in 10 mM sodium phosphate buffer, 
20 mM NaCl, pH 7.4, sonicated for 10 min in an ice bath and centrifuged for 30 minutes 
at 14,000 rcf and 4⁰C (Centrifuge 5804 R, Eppendorf AG, Hamburg Germany).  The 
concentration was estimated using the extinction coefficient of tyrosine, which is 1,280 
M-1cm-1 at 280 nm using a Varian Cary Bio 50 UV-Vis spectrophotometer (Varian, Palo 
Alto, CA)[6].  Peptide concentrations ranged from 70-80 μM and were normalized in all 
the spectral processing. Aβ was prepared and incubated at 37oC for a 12-day time 
period.  During this time, samples were characterized every two days by CD 
spectroscopy.  Stock solutions of each polyphenolic compound were prepared in 
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ethanol at a concentration of 5 mM.  Polyphenolic compounds were then added to the 
protein solutions on Day 6, mid-way through the incubation period, for a final 
concentration of 25 μM.   
4.3.3   Circular Dichroism (CD) 
A Jasco J-815 CD Spectropolarimeter (Jasco, Easton, MD) was used to collect CD 
spectra in the range of 190-250 nm.  A scan speed of 50 nm/min with a response time of 
4 sec was used.  Five spectra were averaged for each sample.  A 1 mm optical path 
length quartz cuvette (Hellman, Plainview, NY) was employed for all measurements.  
4.3.4   Thioflavin T Assays  
Fluorescence was measured on a Cary Eclipse spectrometer (Varian, Palo Alto, 
CA).  A 3 mm path length quartz cuvette (Hellman Plainview, NY) was employed for all 
measurements.  The emission spectra were measured using an excitation wavelength of 
450 nm, and the fluorescence was collected from 470-700 nm.  
4.3.5   Data Analysis  
Data analysis was carried out in the MATLAB R206b (MathWorks, Natick, MA) 
environment.  For CD, all spectra were averaged and the background buffer spectrum 
was subtracted from the raw data.  The mean residue ellipticity (θMRE) was calculated 
using Equation 1 with θ being the raw ellipticity from the measurement (degrees), MW 
being the molecular weight of the protein (g/mol), n being the number of protein 
residues, d being the path length of the cell (cm), and C being the concentration of the 
sample (M).[6-8]  All spectra were the average of triplicate trials.  
Equation 1:       
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4.4   Results  
 
4.4.1   Aβ Untreated  
 
Aβ samples were prepared and incubated for 12 days. Figure 4.2 shows the CD 
spectra of Aβ incubated at 37oC over a 12-day period.  On Day 0, the CD spectrum 
indicates that the protein is predominantly disordered.  By Day 6, the protein was 
beginning to form β-sheet structure. The ThT assays indicated that the increase in β-
sheet formation was associated with an increase in fibrils which is correlated with an 
increase in ThT fluorescence intensity (Figure 4.3).  The CD spectra of Aβ on Days 8-12 
indicate the complete loss of any disordered content. A single minimum present around 
217 nm indicated that the peptide is predominantly β-sheet structured. There is a 
general loss in the overall intensity of the CD spectra in a manner that would suggest 
that the protein concentration may be decreasing over time. It is possible that more of 
the protein starts to form β-sheet structures, small oligomers form. These oligomers can 
be soluble or insoluble. The insoluble oligomers may fall out of solution causing the 
spectrum to lose intensity in all regions.  
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Figure 4.2:  CD spectra of Aβ42 over a 12-day incubation period; Day 0 (black), Day 2 (blue), Day 
4 (red), Day 6 (green), Day 8 (cyan), Day 10 (pink), and Day 12 (yellow).  
 
 
 
Figure 4.3:  ThT fluorescence of Aβ42 fibrillization over a 14-day incubation period. 
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4.4.2   Piceatannol  
 Piceatannol, which has four hydroxyl substituents, shifted the structure of Aβ 
from β-sheet to disordered which is evidenced by the re-emergence of a minima at 197 
nm in the CD spectra (Figure 4.4).  The CD spectra did not change dramatically over the 
remaining 6 days, though the minima at 217 nm decreased in intensity slightly indicating 
a small progressive loss in the remaining β-sheet content.  
 
Figure 4.4:  CD spectra of Aβ42 treated with piceatannol midway during a 12-day incubation 
period. The Aβ protein was treated with piceatannol on Day 6 (black). The protein continued to 
incubate through Day 8 (blue), Day 10 (red), and Day 12 (green).  
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4.4.3   Resveratrol  
Resveratrol, which has three hydroxyl substituents, also shifted the structure of 
Aβ from β-sheet to disordered, based on the appearance of a minima at 197 nm in the 
CD spectrum (Figure 4.5). Although the addition of piceatannol and resveratrol had very 
similar immediate effects on Aβ’s structure, the minima at 197 nm completely 
disappeared between Days 10 and 12 indicating the resveratrol did not prevent β-sheet 
formation after destabilizing fibrils. These data indicate that resveratrol can destabilize 
the β-sheet structure in the fibrils or protofibrils but is not able to prevent their re-
formation. It is possible that oxidation of resveratrol makes it less effective at later 
points. In Chapter 2, it was observed the resveratrol delayed but did not prevent β-sheet 
formation, which is consistent with these results.  
 
Figure 4.5:  CD spectra of Aβ42 treated with resveratrol midway during a 12-day incubation 
period. The Aβ protein was treated with resveratrol on Day 6 (black). The protein continued to 
incubate through Day 8 (blue), Day 10 (red), and Day 12 (green).  
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4.4.4   Diethylstilbestrol 
 
Diethylstilbestrol, which has two hydroxyl substituents, appears to promote β-
sheet formation as evidenced by a stronger minima at 215 nm (Figure 4.6).  On Day 6, 
with the addition of the polyphenol to the Aβ sample, a very small feature with a 
minimum at 197 nm is seen, however this feature is small in comparison to the other 
minimum at 215 nm.  By Day 8, this feature is no longer present in the CD spectrum and 
the protein continues to stay predominantly β-sheet in structure.  The overall loss in 
intensity of the spectra is similar to that of the untreated Aβ sample most likely due to 
the formation of insoluble small oligomers.  
 
Figure 4.6:  CD spectra of Aβ42 treated with diethylstilbestrol midway during a 12-day incubation 
period. The Aβ protein was treated with diethylstilbestrol on Day 6 (black). The protein continued 
to incubate through Day 8 (blue), Day 10 (red), and Day 12 (green). 
  
  4.5   Discussion  
 
As the number of hydroxyl substituents is increased on the rings, the polyphenol 
is more capable of destabilizing the pre-formed Aβ fibrils. Piceatannol, with 4 hydroxyl 
groups, has an immediate effect on the secondary structure, changing the structure of 
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the Aβ protein from β-sheet to disordered. This effect remained throughout the 
incubation period. Resveratrol, with 3 hydroxyl groups, initially promoted disordered 
structure in the Aβ protein, however the polyphenol was incapable of preventing the 
protein from reforming fibrils potentially due to a loss of activity over time. 
Diethylstilbestrol, with only 2 hydroxyl groups, had a limited initial effect on the 
protein’s structure. The protein formed predominantly β-sheet structure similar to the 
untreated Aβ solution.  
Figure 4.7 shows the intensity of the CD spectra of untreated and treated 
samples at 217 nm.  Evaluation of the intensity of the CD spectra at 217 nm, shows that 
the structure of the piceatannol-treated sample is relatively stable over time. The 
resveratrol-treated Aβ sample is also is fairly stable with changes in structure occurring 
after Day 10.  The diethylstilbestrol-treated Aβ sample has the most noticeable change 
in structure when compared to the other two polyphenols. Diethylstilbestrol is the least 
effective polyphenol in destabilizing pre-formed Aβ fibrils.  Thus, increasing the number 
of hydroxyl substituents, which increases the antioxidant potency of the polyphenol, 
makes the polyphenol capable of destabilizing pre-formed Aβ fibrils.  
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Figure 4.7:  Intensity changes at 217 nm of the polyphenol-treated and untreated Aβ samples, 
over a 6-day incubation period; piceatannol (purple), resveratrol (pink), diethylstilbestrol (blue), 
and Aβ (black). Error bars are shown based on three repetitive trials.  
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Chapter V: Increasing Chain Linker Polarity Destabilizes Pre-formed 
Amyloid-β Fibrils 
 
5.1   Abstract 
Diaryl polyphenolic compounds have common structural components consisting 
of two phenolic rings with hydroxyl group substituents and a chain linker between the 
rings. The chain between the two phenol rings can vary significantly both in length and 
atom makeup, altering the anti-amyloidgenic properties of the polyphenol.  Flavonoid 
compounds do not contain a chain linker and understanding how the chain linker can 
affect the activity of linear polyphenols is imperative.  The aromatic rings of polyphenols 
are important for their binding to proteins and their effects on protein aggregation.  The 
type of linker between these rings is also important because it could also affect protein 
binding and aggregation. The polyphenols nordihydroguaiaretic acid, curcumin, and 
rosmarinic acid have increasing polarity, respectively, in the chain linker region between 
the phenolic rings. Each of these polyphenols has four ring substituents and 4 - 6 atoms 
in their chain linker. In this study, it was found that all the polyphenols disrupted and at 
least partially reversed fibrillization, though no clear trend with polarity of the linker 
region was observed.  
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5.2   Introduction  
The chain between the two phenol rings can vary significantly both in length and 
atom makeup. These differences have an important impact on how the polyphenol 
metabolizes and behaves.[1-2]  It is suggested that the optimum chain length between 
the rings should be 2-6 atoms long.[3]  Studies have shown that diaryl polyphenols such 
as curcumin, are better than flavonoids at inhibiting the amyloidogenic activity of Aβ 
possibly due to the type of chain linker in between the aromatic rings.[1-2] 
The aromatic rings are important for polyphenol binding to proteins and their 
effect on protein aggregation.  Aromatic rings of polyphenols provide the necessary 
hydrophobic interactions with proteins that can interrupt endogenous hydrophobic 
interactions within the protein which promote aggregation.[3,4-9] The rings of 
polyphenols have the necessary planarity to bind to Aβ in the hydrophobic groove, 
interrupting the π stacking, and preventing aggregation by intercalating within the β-
sheets.[1, 4,10-11]  The chain linker polarity determines the polyphenol’s overall polarity 
and its ability to disrupt the hydrophobic interactions necessary for protein aggregation.  
The polyphenols nordihydroguaiaretic acid, curcumin, and rosmarinic acid have 
increasing polarity respectively in the chain linker region between their phenolic rings. 
Each of these polyphenols has four ring substituents and 4 - 6 atoms in their chain 
linker. In Chapter 3, the effect of polarity in the chain linker region on the structure of 
the Aβ protein during the aggregation process was evaluated. It was shown that 
decreasing the polarity of the chain linker increased the ability of the polyphenol to 
interfere with Aβ fibrillization. Using the same polyphenols, i.e., nordihydroguaiaretic 
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acid, curcumin, and rosmarinic acid, shown in Figure 5.1, it was evaluated whether these 
molecules can also destabilize pre-formed Aβ fibrils.  
  
 
a b c 
Figure 5.1: Structures of nordihydroguaiaretic acid (a), curcumin (b), and rosmarinic acid (c).  
 
5.3    Materials and Methods  
 
5.3.1    Materials 
A(1-42) (>95% pure) was purchased from Atlantic Peptides (Scarborough, ME).  
Ethanol and sodium perchlorate were purchased from Sigma-Aldrich (St. Louis, MO) and 
used without further purification. Sodium phosphate monobasic, sodium phosphate 
dibasic, sodium chloride, and cyclohexane were purchased from Fisher Scientific 
(Pittsburgh, PA).  Thioflavin T, rosmarinic acid, and nordihydroguaiaretic acid were 
purchased from Sigma-Aldrich (St. Louis, MO) and curcumin was purchased from Acros 
Organics (Pittsburgh, PA).  
5.3.2   Methods 
The amyloid-β (1-42) protein was prepared and characterized as described in 
Chapter 4, sections 4.3.2-4.3.4. Circular dichroism (CD) and were analyzed as described 
in Chapter 4, section 4.3.5.  
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5.4   Results  
 
5.4.1   Aβ Untreated  
 
The initial CD spectra of the Aβ protein indicated that the protein was 
predominantly disordered in structure, with a strong minima at 197 nm (Figure 5.2).  By 
Day 6, the protein had formed β-sheet fibrils as evidenced by the characteristic minima 
at 217 nm in the CD spectrum and concurrent increase in ThT fluorescence (Figure 5.3). 
Between Days 8-12 the CD spectra indicate a complete loss of any disordered content as 
the only minimum present is around 217 nm. The CD spectra generally lose overall 
intensity in a manner that would suggest that the protein concentration may be 
decreasing over time.  
 
Figure 5.2: CD spectra of Aβ42 over a 12-day incubation period; Day 0 (black), Day 2 (blue), Day 
4 (red), Day 6 (green), Day 8 (cyan), Day 10 (pink), and Day 12 (yellow).  
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Figure 5.3:  ThT fluorescence of Aβ42 fibrillization over a 14-day incubation period. 
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5.4.2   Nordihydroguaiaretic Acid  
 
Aβ was incubated at 37oC for 6 days.  On Day 6, the polyphenols 
nordihydroguaiaretic acid, curcumin, and rosmarinic acid were added to aliquots of the 
Aβ protein solution. Nordihydroguaiaretic acid, having a nonpolar hydrocarbon chain 
linker, was added to Aβ on Day 6 and the protein remained predominantly β-sheet 
structured, as seen in Figure 5.4. However, a small disordered feature with a minimum 
at 197 nm is seen, showing that there were initial structural perturbation by the 
polyphenol on the protein. By Day 8, a loss in the intensity of the minima at 217 nm is 
observed, which continues through Day 12. By Day 12, the protein is almost completely 
disordered with appearance of the strong minimum at 197 nm and a significant loss of 
the minimum at 217 nm. Although, the effects of nordihydroguaiaretic acid are slow, 
the end result shows that the polyphenol does have the ability to destabilize pre-formed 
Aβ fibrils.  
 
Figure 5.4:  CD spectra of Aβ42 treated with nordihydroguaiaretic acid midway during a 12-day 
incubation period. The Aβ protein was treated with nordihydroguaiaretic acid on Day 6 (black). 
The protein continued to incubate through Day 8 (blue), Day 10 (red), and Day 12 (green).  
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5.4.3   Curcumin 
 
Curcumin, has a more polar chain linker than nordihydroguaiaretic acid. When 
curcumin was added to the Aβ sample on Day 6, the protein’s structure stopped 
changing for the remainder of the incubation period. Additionally, curcumin 
immediately caused the protein to shift structure from predominantly β-sheet to 
partially disordered, as seen in Figure 5.5. Curcumin seems to stabilize the protein in an 
intermediate state with both disordered and β-sheet structures. With curcumin, the 
minimum at 197 nm indicative of disordered structure is more intense than the 
minimum at 217 nm which is indicative of β-sheet structure, showing that the 
destabilizing effects of curcumin are strong.   
 
Figure 5.5:  CD spectra of Aβ42 treated with curcumin midway during a 12-day incubation 
period. The Aβ protein was treated with curcumin on Day 6 (black). The protein continued to 
incubate through Day 8 (blue), Day 10 (red), and Day 12 (green).  
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5.4.4   Rosmarinic Acid  
Rosmarinic acid has the most polar chain linker. Again, it was added to the Aβ 
sample on Day 6. The structure of the protein immediately shifted toward a more 
disordered state with the minimum at 197 nm strengthening, as seen in Figure 5.6.   
There was still a slight feature at 217 nm suggestive of residual β-sheet structure, 
however the intensity of this feature reduces at each of the following time points.  
 
Figure 5.6:  CD spectra of Aβ42 treated with rosmarinic acid midway during a 12-day incubation 
period. The Aβ protein was treated with rosmarinic acid on Day 6 (black). The protein continued 
to incubate through Day 8 (blue), Day 10 (red), and Day 12 (green).  
 
5.5    Discussion  
 
Each of the polyphenols tested here caused a shift from β-sheet to more 
disordered structure when added to pre-formed fibrils. However, the effect manifested 
differently for each polyphenol.  Interestingly nordihydroguaiaretic acid appeared to 
initially promote β-sheet structure and then disrupt it over the remaining 6 days of 
incubation. Curcumin on the other hand, appeared to freeze Aβ in an intermediate state 
containing significant amounts of both disordered and β-sheet structures. Rosmarinic 
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acid also shifted the overall structure of Aβ toward disordered structure and continued 
to do so throughout the experiment. Although there is no clear trend with the increase 
in the polarity of the chain linker region, all three polyphenols disrupted the fibrillization 
process. Nordihydroguaiaretic acid and rosmarinic acid continued to disrupt fibrils 
throughout the remaining incubation period but curcumin appeared to freeze the 
peptide in an intermediate state. Curcumin has the longest linker region between the 
phenols, which may be a factor.   
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Chapter VI: Conclusions 
 
The aggregation pathway of the amyloid-β protein can be altered by introduction 
of polyphenolic compounds. This alteration can occur during the formation and 
extension stages of the aggregation, or during the destabilization stage of the pathway. 
How a polyphenol behaves when introduced to the protein solution is dependent both 
on chain linker polarity and number of hydroxyl ring substituents on the polyphenol. 
This investigation examined the effects of nordihydroguaiaretic acid, curcumin, 
rosmarinic acid, resveratrol, piceatannol, and diethylstilbestrol on Aβ aggregation and 
destabilization using circular dichroism and deep ultraviolet resonance Raman 
spectroscopies.  
Increasing the number of ring substitutions was correlated with an increased 
ability to prevent of the formation of fibrils and also to destabilize pre-formed fibrils. 
Increasing the hydroxyl group substituents on the polyphenol likely facilitates increased 
hydrogen bonding required with Aβ. The polyphenols diethylstilbestrol, resveratrol, and 
piceatannol have increasing numbers of hydroxyl substituents on their rings, having two, 
three, and four respectively.  Piceatannol, having the greatest number of hydroxyl 
substituents has the highest efficacy in preventing formation of fibrils and destabilizing 
pre-formed fibrils.  
Increasing the polarity of the chain linker resulted in decreased stability of the 
protein during the aggregation process. The nonpolar chain linker of 
nordihydroguaiaretic acid preserved the disordered structure of the Aβ protein and 
prevented it from forming β-sheet structure. Conversely, rosmarinic acid having the 
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most polar chain linker was not able to perform in the same manner, increasing the 
amount of β-sheet structure in the protein solution. Nordihydroguaiaretic acid, 
curcumin, and rosmarinic acid were able to disrupt pre-formed Aβ fibrils, each at its own 
rate, however the final state was similar regardless of added polyphenol.  Decreasing 
the polarity of the chain linker would be optimal in order to prevent, or slow, the 
formation of fibrils while still having the ability to destabilize pre-formed Aβ fibrils as 
well.  
Future studies including a wider array of polyphenols with varying phenolic ring 
substitutions and chain linkers is necessary to confirm the results shown here. Amyloid-
β has many unique fragments within its 42 residues which all play a different role in how 
the protein aggregates. Examples of these fragments include the transmembrane 
region, extracellular region, glycine zipper motifs, HHQK motif, and KLVFF motif.  
Investigating how the different structural components of the polyphenols affect each of 
these Aβ fragments is crucial to gain a full understanding on how they are playing a role 
in the complete aggregation pathway of Aβ.  
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